The Effectiveness And Safety Of Alteplase And Batroxobin In Treatment Of Acute Cerebral Infarction

Objective:Based on the Comparison of efficacy and safety between alteplase and batroxobin treatment of acute cerebral infarction, to provide evidence for the clinical to make a reasonable choice for treatment of early acute cerebral infarction.Methods:Cases source selection in March 2013 to March 2015 in one hospital of Heilongjiang neurology clinic of atenolol general intravenous thrombolysis alteplase treatment of 50 cases of patients with acute ischemic stroke, with the same period of batroxobin intravenous thrombolytic therapy with the same conditions of patients 50 cases as control group. Conditions in accordance with the standards of the group,eligible patients signed written informed consent given into groups.Result:1. After treatment, compare before treatment the nerve function in patients with different degrees of improvement, and the average of ESS significantly improved after treatment,the difference was statistically significant(P <0.05). The difference before treatment between the two group was not statistically significant(P> 0.05),after treatment the alteplase group increased more obvious than the batroxobin group and the difference was statistically significant(P <0.05).2. After treatment, along with the recovery time becomes longer Barthel index were significantly improved. After treatment 24 h, 14 d the Barthel index difference between the two groups was not statistically significant, but after treatment 90 d alteplase group Barthel index was significantly higher than the batroxobin group, the difference was statistically significant(P <0.05).3.Alteplase group have 1 case intracanial hemorrhage,with symptomatic cerebral hemorrhage.Totally 2 cases combined with cerebral hemorrhage about Batroxobin group,which are symptomatic intracranial and Asymptomatic cerebral hemorrhage;The alteplase group had 2 cases of infarct hemorrhage, 2 cases of leeding gums, 3cases of red blood cells in urine, no chills, allergies and other adverse reactions.Symptomatic treatment and the adverse reactions disappear. There was no intracranial hemorrhage in the batroxobin group, and no deaths were reported with the two groups. Bleeding and mortality rates between the two groups were not statistically significant(P> 0.05).Conclusion:1. In this study, intravenous thrombolysis in acute cerebral infarction select alteplase and batroxobin before and after treatment were significantly improved in patients to improve neurological function, helping patients improve life skills.2. In this experiment, two groups of neurological recovery were different, and the alteplase group in the recovery of neurological function after treatment was better than the batroxobin group.3. In this experiment, there were significant differences of patients at the 90 days after treatment in the ability to improve the lives, the patients treated with alteplase were significantly better than batroxobin group.4. By analyzing the incidence of adverse reactions of the two groups, between the two groups there was no significant statistically difference, so the use of alteplase is safe and effective.5.It indicated in our research that Alteplase curative effect is better than Batroxobin for acute cerebral infarction winthin the early time window.